文献速递肿瘤 PET/CT骨显像与常规 SPECT

[18F]PSMA-1007 PET/CT 在前列腺癌生化复发中的诊断准确性

Diagnostic accuracy of [18F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-01-24

该研究回顾性分析177例因生化复发前列腺癌行[18F]PSMA-1007 PET/CT 的患者,按六个身体区域计算诊断准确性。在81例可获得确诊随访的患者中,总体灵敏度95%、特异度89%、阳性预测值86%、阴性预测值96%;骨病灶阳性预测值仅79%,为潜在诊断薄弱点。

要点

  • [18F]PSMA-1007 PET/CT 在生化复发前列腺癌中总体 PET 阳性率为91%。
  • 可确诊随访的81例患者中,总体灵敏度95%、特异度89%、阳性预测值86%、阴性预测值96%。
  • 骨病灶阳性预测值为79%,为使用该示踪剂时的潜在诊断薄弱点。

核心结论

  • [18F]PSMA-1007 PET/CT 在生化复发前列腺癌中已知的高 PET 阳性率得到证实,按区域分析具有相应的高(>90%)灵敏度和阴性预测值。
  • 然而总体阳性预测值有限(86%),尤其是骨病灶(79%),为使用该示踪剂时的潜在诊断薄弱点。

研究设计与样本

  • 回顾性分析177例因生化复发前列腺癌连续接受[18F]PSMA-1007 PET/CT 的患者。
  • 定义六个身体区域:前列腺床、盆腔淋巴结、腹膜后淋巴结、膈上淋巴结、骨和软组织。
  • 区域阳性定义为观察到至少一个可疑前列腺癌的 PSMA 阳性病灶。
  • 真阳性确认标准为组织病理学阳性、靶向治疗后血清前列腺特异性抗原(PSA)下降>50%,或进一步 CT、MRI、PET/CT 或骨扫描影像确认。
  • 真阴性定义为额外影像能确认无可疑前列腺癌病灶的区域,或 exclusively 靶向放疗以外区域且血清 PSA 下降>50%。

主要发现

  • 总体 PET 阳性率为91%。
  • 81/152例患者可获得对 PSMA 阳性病灶确认或否定的结论性随访(按区域分析)。
  • 该亚组总体灵敏度95%(CI:0.90-0.98)、特异度89%(CI:0.83-0.93)、阳性预测值86%(0.80-0.90)、阴性预测值96%(CI:0.92-0.98)。
  • 按区域阳性预测值:局部复发97%(CI:0.83-0.99)、盆腔淋巴结93%(CI:0.78-0.98)、腹膜后淋巴结87%(CI:0.62-0.96)、膈上淋巴结82%(CI:0.52-0.95)、骨病灶79%(0.65-0.89)。
  • 实性器官转移灶数量(n=6)太少,无法进行准确统计分析。

关键数值与推荐

  • 总体灵敏度95%(CI:0.90-0.98)、特异度89%(CI:0.83-0.93)、阳性预测值86%(0.80-0.90)、阴性预测值96%(CI:0.92-0.98),基于81例可确诊随访患者按区域分析。
  • 局部复发阳性预测值97%(CI:0.83-0.99)。
  • 盆腔淋巴结阳性预测值93%(CI:0.78-0.98)。
  • 腹膜后淋巴结阳性预测值87%(CI:0.62-0.96)。
  • 膈上淋巴结阳性预测值82%(CI:0.52-0.95);骨病灶阳性预测值79%(0.65-0.89)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 实性器官转移灶数量(n=6)太少,无法进行准确统计分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Despite increasing use for the detection of biochemically recurrent prostate cancer (rPC), the diagnostic accuracy of positron emission tomography/computed tomography (PET/CT) with [18F]PSMA-1007 remains only partially investigated. The aim of this study was to determine the sensitivity (SE), specificity (SP), positive predictive value (PPV), and negative predictive value (NPV) for PC-local recurrence and metastases on a per region basis. MATERIALS AND METHODS: One hundred seventy-seven consecutive patients undergoing [18F]PSMA-1007 PET/CT for rPC were retrospectively analysed. Six body regions were defined: prostate fossa, pelvic lymph nodes (LN), retroperitoneal LN, supradiaphragmatic LN, bones, and soft tissue. A region was counted positive if at least one PSMA-positive lesion suspicious for PC was observed. Confirmation of a true-positive PSMA-avid lesion was defined as positive by histopathology, fall in serum prostate-specific antigen (PSA) (> 50%) after targeted therapy or confirmatory further CT, MRI, PET/CT, or bone scan imaging. Regions where additional imaging was able to confirm the absence of suspicious PC lesions or regions outside exclusively targeted RT with serum PSA decline (> 50%) were counted as true-negative regions. SE, SP, PPV, and NPV were calculated for all six regions. RESULTS: The overall PET-positivity rate was 91%. Conclusive follow-up for affirmation or refutation of a PSMA-positive lesion was available for 81/152 patients on a per region basis. In this subgroup, overall sensitivity, specificity, PPV, and NPV were 95% (CI: 0.90-0.98), 89% (CI: 0.83-0.93), 86% (0.80-0.90), and 96% (CI: 0.92-0.98), respectively. On a per region basis, PPV was 97% (CI: 0.83-0.99) for local recurrence, 93% (CI: 0.78-0.98) for pelvic LN, 87% (CI: 0.62-0.96) for retroperitoneal LN, 82% (CI: 0.52-0.95) for supradiaphragmatic LN, and 79% (0.65-0.89) for bone lesions. The number of solid organ metastases (n = 6) was too small for an accurate statistical analysis. CONCLUSION: The known high PET-positivity rate of [18F]PSMA-1007 PET/CT in rPC was confirmed, with corresponding high (> 90%) sensitivity and NPV on a per region basis. However, overall PPV was limited (86%), particularly for bone lesions (79%), which are a potential diagnostic weaknesses when using this tracer.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Mingels C, Bohn KP, Rominger A, et al. Diagnostic accuracy of [18F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2022. PMID: 35067735. doi:10.1007/s00259-022-05693-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。